MXPA04003547A - Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido. - Google Patents

Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido.

Info

Publication number
MXPA04003547A
MXPA04003547A MXPA04003547A MXPA04003547A MXPA04003547A MX PA04003547 A MXPA04003547 A MX PA04003547A MX PA04003547 A MXPA04003547 A MX PA04003547A MX PA04003547 A MXPA04003547 A MX PA04003547A MX PA04003547 A MXPA04003547 A MX PA04003547A
Authority
MX
Mexico
Prior art keywords
tfpi
sepsis
tissue factor
pathway inhibitor
factor pathway
Prior art date
Application number
MXPA04003547A
Other languages
English (en)
Inventor
A Creasey Alba
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of MXPA04003547A publication Critical patent/MXPA04003547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a metodos para tratar profilactica o terapeuticamente la sepsis o choque septico que involucran la administracion de un inhibidor de la via de factor de tejido (TFPI) o un analogo de TFPI a pacientes que sufren de sepsis u otras condiciones inflamatorias. Los metodos involucran el uso de la infusion intravenosa, continua de TFPI o un analogo de TFPI, en dosis bajas para evitar los efectos colaterales adversos.
MXPA04003547A 2001-10-15 2002-10-15 Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido. MXPA04003547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32880601P 2001-10-15 2001-10-15
PCT/US2002/032625 WO2003055442A2 (en) 2001-10-15 2002-10-15 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
MXPA04003547A true MXPA04003547A (es) 2004-07-22

Family

ID=23282520

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04003547A MXPA04003547A (es) 2001-10-15 2002-10-15 Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido.
MXPA04003548A MXPA04003548A (es) 2001-10-15 2004-04-15 Tratamiento de neumonia severa mediante administracion de inhibidor de via factor de tejido.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA04003548A MXPA04003548A (es) 2001-10-15 2004-04-15 Tratamiento de neumonia severa mediante administracion de inhibidor de via factor de tejido.

Country Status (17)

Country Link
US (2) US7674769B2 (es)
EP (2) EP1446140A4 (es)
JP (5) JP2005515214A (es)
KR (2) KR20040040489A (es)
CN (2) CN1604787A (es)
AU (2) AU2002365131B2 (es)
BR (2) BR0213292A (es)
CA (2) CA2463655A1 (es)
EA (2) EA200400548A1 (es)
HU (2) HUP0500472A2 (es)
IL (2) IL161408A0 (es)
IS (2) IS7223A (es)
MX (2) MXPA04003547A (es)
NO (2) NO20041997D0 (es)
PL (2) PL372138A1 (es)
WO (2) WO2003055442A2 (es)
ZA (2) ZA200403601B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200400548A1 (ru) * 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
WO2004062646A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
EP1654283B1 (en) 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Improved method of purifying tfpi and tfpi analogs
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
KR20080033151A (ko) * 2005-04-15 2008-04-16 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 조직인자경로억제제(ｔｆｐｉ)의 투여에 의한중증지역사회획득 폐렴의 치료
US20090214506A1 (en) * 2005-05-06 2009-08-27 Novartis Ag Use of TFPI to Treat Severe Bacterial Infections
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US20100279925A1 (en) * 2005-06-24 2010-11-04 Lars Otto Uttenthal Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract
BRPI0613676A2 (pt) * 2005-07-22 2011-01-25 Novartis Ag polipeptìdeo, seu uso e composição farmacêutica compreendendo o mesmo
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
DK2734547T3 (en) 2011-07-18 2017-04-03 Univ Melbourne USE OF C-FMS ANTIBODIES
PL2781221T3 (pl) * 2011-11-15 2020-08-24 Asahi Kasei Pharma Corporation Lek do leczenia i/lub uzyskiwania poprawy w posocznicy
JP2016516092A (ja) 2013-04-12 2016-06-02 モルフォシス・アー・ゲー Ｍ−ｃｓｆを標的とする抗体
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
WO2023142096A1 (en) * 2022-01-30 2023-08-03 Westlake University Composition and method for preventing and/or treating clostridioides difficile infections caused by clade 2 strains

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
EP0179861A1 (en) 1984-04-19 1986-05-07 Agracetus Methods and vectors for transformation of plant cells
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5110730A (en) 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK412389D0 (da) 1989-01-19 1989-01-19 Novo Nordisk As Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK148890D0 (da) 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
ES2085462T3 (es) 1990-08-27 1996-06-01 Monsanto Co Combinacion anticoagulante de laci y de polisacaridos sulfatados.
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
USRE36476E (en) 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US5276015A (en) 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
WO1993024143A1 (en) 1992-06-01 1993-12-09 Cetus Oncology Corporation A method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
KR950701820A (ko) 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
JP3761914B2 (ja) * 1994-11-17 2006-03-29 財団法人化学及血清療法研究所 アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5612363A (en) 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US6323326B1 (en) * 1995-06-07 2001-11-27 Chiron Corporation Method of solubilizing, purifying, and refolding protein
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US5885781A (en) 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
DE69726281T2 (de) 1996-03-25 2004-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
US5977057A (en) 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
AU6042298A (en) * 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
NZ337828A (en) 1997-04-28 2001-06-29 Lilly Co Eli Activated protein C formulations having a bulking agent and a salt
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
BR9915460A (pt) 1998-11-20 2001-07-17 Lilly Co Eli Método de tratamento de febre hemorrágica virótica
WO2000077254A1 (en) * 1999-06-11 2000-12-21 The Government Of The United States Of America As Represented By The Secretary, Of The Department Of Health And Human Services Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection
AU5062100A (en) 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
US6294648B1 (en) 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
BR0014486A (pt) 1999-10-04 2002-09-17 Chiron Corp Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
AU2908501A (en) 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
EP1267904A4 (en) 2000-02-16 2006-02-08 Univ Northwestern POLYPEPTIDE PULMONAL TENSIDES
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6756208B2 (en) 2001-02-28 2004-06-29 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
EP1383885A4 (en) 2001-04-04 2005-11-30 American Diagnostica Inc METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EA200400548A1 (ru) 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
US20020198138A1 (en) 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
JP2005506345A (ja) 2005-03-03
EA200400549A1 (ru) 2005-02-24
HUP0500472A2 (hu) 2005-08-29
US20030139340A1 (en) 2003-07-24
AU2002365131A1 (en) 2003-07-15
AU2002340183B2 (en) 2008-11-13
EA200400548A1 (ru) 2005-06-30
EP1446140A4 (en) 2007-03-07
BR0213293A (pt) 2004-12-21
HUP0501111A2 (en) 2007-12-28
CN1604790A (zh) 2005-04-06
EP1446140A2 (en) 2004-08-18
JP2005515214A (ja) 2005-05-26
KR20050036867A (ko) 2005-04-20
BR0213292A (pt) 2006-05-23
JP2006008704A (ja) 2006-01-12
IL161407A0 (en) 2004-09-27
NO20041997D0 (no) 2004-05-14
JP2010006839A (ja) 2010-01-14
ZA200403601B (en) 2006-06-28
PL372138A1 (en) 2005-07-11
JP2006008706A (ja) 2006-01-12
US20030139339A1 (en) 2003-07-24
MXPA04003548A (es) 2004-07-22
IL161408A0 (en) 2004-09-27
WO2003055442A3 (en) 2004-03-04
EP1446138A2 (en) 2004-08-18
CA2463655A1 (en) 2003-04-24
EP1446138A4 (en) 2007-03-14
CN1604787A (zh) 2005-04-06
CA2463738A1 (en) 2003-07-10
NO20041996D0 (no) 2004-05-14
WO2003032904A2 (en) 2003-04-24
KR20040040489A (ko) 2004-05-12
ZA200403690B (en) 2005-03-08
IS7223A (is) 2004-04-15
PL374506A1 (en) 2005-10-31
US7674769B2 (en) 2010-03-09
WO2003055442A2 (en) 2003-07-10
WO2003032904A3 (en) 2004-03-04
IS7224A (is) 2004-04-15
AU2002365131B2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
MXPA04003547A (es) Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido.
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
CA2241904A1 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
ATE305469T1 (de) Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklyl midverbindungen
WO2002089805A3 (en) Use of regularly scheduled high dose intravenous methotrexate therapy
RU2003125274A (ru) Применение флумазенила в производстве лекарства для лечения алкогольной зависимости
GB0130677D0 (en) Medicaments and novel compounds
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
HUP0301828A2 (hu) Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
HUP0001263A2 (hu) Eljárások anti-CD4OL vegyületek gyógyászati alkalmazásaira
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
SE9902597D0 (sv) New use
TNSN06295A1 (en) Treatment of severe community - acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
TNSN07386A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
IL146962A0 (en) Aminotetralin derivatives for the therapy of cardiovascular diseases
TW200621794A (en) Pulmonary administration of an antithrombotic compound
DK1399141T3 (da) Anvendelse af acetyl L-carnitin til fremstilling af et lægemiddel til forebyggende terapi af post-kirurgisk smerte
NO20075898L (no) Behandling av samfunnsvervet lungebetennelse ved administrering av vevsfaktor pathway inhibitor (TFPI)